📰 Adicet News
Adicet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adicet. Real-time updates on events, politics, business and more.
May 31, 2023
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31,... | May 31, 2023
April 28, 2023
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April 28,... | April 28, 2023
April 13, 2023
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive... | April 13, 2023
March 31, 2023
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March 31,... | March 31, 2023
November 1, 2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief
October 31, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on October 31,... | October 31, 2022
August 10, 2022
WASHINGTON (dpa-AFX) - Adicet Bio, Inc. (ACET) reported a second quarter net loss attributable to common shareholders of $22.5 million, or a net loss of $0.56 per share, as compared to a net loss
June 3, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on May 31,... | June 3, 2022
April 19, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today announced the... | April 19, 2022
March 15, 2022
WASHINGTON (dpa-AFX) - Adicet Bio, Inc (ACET) released Loss for its fourth quarter that increased from last year and missed the Street estimates.The company's earnings totaled -$15.81 million,